Marking area. Siegfried opens a fifteen million euro pharmaceutical product development center in Barbera del Valles, Barcelona. The new Catalan plant has advanced laboratory facilities and dynamic development capabilities.
The new property It has a total area of 1,500 square meters and will have more than forty specialists qualified for drug development. The center will be of great importance in providing services to the pharmaceutical industry from product development to product marketing.
The company produces oral products at these facilities, allowing it to offer additional services in this market. The development center has state-of-the-art laboratories and state-of-the-art facilities, built in a span of two years, and offers a range of services to its customers.
Sigfried maintains the brand in Spain with two pharmaceutical plants in Barcelona.
Wolfgang Weinand, CEO of Siegfried, said: “This center strengthens our global network and improves our growth; this investment reinforces our commitment to provide our customers with the most advanced skills and capabilities in the development and production of pharmaceutical products.
In the year In 2022, the company’s net sales of 1,229 million Swiss francs (1,248 million euros) are supported by both pharmaceuticals and pharmaceutical products, which represents an increase of 15.6% compared to 2021. The gross profit margin (Ebitda) of Switzerland is 2. 276 million euros), 31 percent more than last year.
Net profit increased by 34%, to 127 million Swiss francs (129 million euros). The board of directors proposes to the annual general meeting to increase the payment to shareholders to 3.4 Swiss francs (3.4 euros) per share.
Winand said: “In 2022, our global team has taken important steps to further strengthen our position as a global leader in the CDMO space and we will continue to invest in our people and network to deliver long-term profitable growth. Going forward.. we are committed to continue the entrepreneurial spirit that many generations before us have created.